Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lupus Clear all
Completed Phase 2 Interventional Results available

A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector

NCT02124798
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab autoinjector
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

NCT04925934
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
VIB7734, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Upland, California • Clearwater, Florida • Ormond Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus

NCT02456168
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 21, 2026, 1:22 AM EDT
Not listed Phase 3 Interventional

Study of GL701 in Men With Systemic Lupus Erythematosus

NCT00037128
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GL701
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

NCT03288324
View directory record Official record
Conditions
Cutaneous Lupus, Systemic Lupus Erythematosus
Interventions
Tofacitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

NCT05123586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 1 Interventional

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

NCT00325741
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Hematopoietic Cell Transplantation
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

NCT01930890
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BIIB023, mycophenolate mofetil, oral corticosteroids
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 76 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Lake Success, New York • Columbus, Ohio • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 3 Interventional

Evaluation of Walk With Ease in Arthritis

NCT00526435
View directory record Official record
Conditions
Arthritis
Interventions
Walk with Ease - Group, Walk with Ease - Self
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 90 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048776
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Pletal
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
5 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
19
States / cities
Anchorage, Alaska • Fresno, California • Madera, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting Phase 2 Interventional

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

NCT07053800
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obecabtagene autoleucel
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
New York, New York • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus

NCT03142711
View directory record Official record
Conditions
SLE, Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus
Interventions
No Medical Intervention
Other
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 21, 2026, 1:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Glendale, Arizona • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

NCT01709474
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Vitamin D3 6000 IU, Vitamin D3 400 IU
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Not listed Not applicable Interventional

Delivery of Enhance Fitness Trial

NCT05275348
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis, Fibromyalgia, Gout, Osteoarthritis, Lupus or SLE
Interventions
Tele-Enhance Fitness, In-person Enhance Fitness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Not applicable Interventional Results available

Addressing Disparities in Lupus Care Through an Integrated Care Management Program

NCT03915652
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Rheum iCMP
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting Not applicable Interventional

Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous

NCT07713940
View directory record Official record
Conditions
Systemic Lupus Erthematosus (SLE)
Interventions
anti-inflammatory diet
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational

Patient-Centered Assessment of Symptoms and Outcomes

NCT03952624
View directory record Official record
Conditions
Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of ITGAM in Systemic Lupus Erythematosus

NCT01230112
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational

Cutaneous Lupus Medication Experience Study

NCT02176148
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
fluocinonide 0.05% cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 21, 2026, 1:22 AM EDT